"The study adds to growing evidence that dupilumab, while highly effective for managing atopic dermatitis, may also be linked ...

CSPC Pharmaceutical Group ( ($HK:1093) ) has issued an update. CSPC Pharmaceutical Group has announced that its Dupilumab Injection, a biosimilar ...

For nearly a decade, 71-year-old Ho Thian Kong struggled with the effects of chronic rhinosinusitis with nasal polyps, a ...

For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...

The intervention being tested is Dupilumab, a drug administered via subcutaneous injection. It is intended to manage symptoms of PN, particularly the intense itching associated with the condition.

Identifying specific biomarkers and clinical characteristics is crucial for predicting a patient's response to both existing and emerging treatments for chronic spontaneous urticaria, thereby moving ...

Dupixent shows potential as a treatment for atopic dermatitis, alopecia and vitiligo, targeting shared immune pathways for ...

Dupilumab may provide a nonsteroidal option for managing cancer therapy-related skin toxicities, according to a study.

In August 2025, NexEos Diagnostics Inc . announced phase 2 study to assess the safety and exploratory diagnostic performance ...